Spots Global Cancer Trial Database for Study of XL999 in Patients With Acute Myeloid Leukemia (AML)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of XL999 in Patients With Acute Myeloid Leukemia (AML)
Official Title: A Phase 2 Study of XL999 Administered Intravenously to Subjects With Acute Myeloid Leukemia
Study ID: NCT00322673
Interventions
Study Description
Brief Summary: This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL999 when given weekly to patients with relapsed or newly-diagnosed AML. XL999 is a small molecule inhibitor against Flk1/kinase insert domain receptor (KDR), PDGFR, c-Kit, FLT3 and SRC. c-Kit and FLT3 are receptors commonly expressed on AML blasts.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Eddie Hu, Alhambra, California, United States
Ronald Paquette, Los Angeles, California, United States
The Thomas and Dorothy Leavey Cancer Center, Northridge, California, United States
David Chan, Redondo Beach, California, United States
Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology, Chicago, Illinois, United States
American Health Network of Indiana, Indianapolis, Indiana, United States
Section of Hematology/Oncology Indiana Cancer Pavilion, Indianapolis, Indiana, United States
Contact Details
Name: Lynne Bui, MD
Affiliation: Exelixis
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
